Shenzhen Kangvape Technology Co., Ltd – Trademark Portfolio

Entity Type: 99

Shenzhen Kangvape Technology Co., Ltd holds 30 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 34 (Smokers Articles) — 30 filings in this category. Currently, 20 trademarks are registered and 4 are pending. Notable registered marks include SOOCE, YIBLA, KEEPALL, DAUPHINE, and FASTTIME.

2F, 5F, No.3 Building,

Hanyu Bay Area Innovation Port, Liyuan Road, Tangwei Community, Fuhai Street, Baoan District, Shenzhen 518100 Guangdong

30 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Page 1 of 2 (30 results)

Trademark Classifications

Shenzhen Kangvape Technology Co., Ltd's trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

34
Smokers Articles (30 filings)

Tobacco; smokers articles; matches

Frequently Asked Questions

How many trademarks does Shenzhen Kangvape Technology Co., Ltd have?

Shenzhen Kangvape Technology Co., Ltd has 30 U.S. trademarks filed with the USPTO. Of these, 20 registered, 4 pending, 6 abandoned.

What trademark classes does Shenzhen Kangvape Technology Co., Ltd file in?

Shenzhen Kangvape Technology Co., Ltd files trademarks across 1 Nice Classification class. The most active classes are Class 34 (Smokers Articles). Class 34 covers tobacco; smokers articles; matches.

What are Shenzhen Kangvape Technology Co., Ltd's most well-known trademarks?

Shenzhen Kangvape Technology Co., Ltd's registered trademark portfolio includes well-known marks such as SOOCE, YIBLA, KEEPALL, DAUPHINE, and FASTTIME. These are among 20 currently registered trademarks in the portfolio.

What is Shenzhen Kangvape Technology Co., Ltd's trademark registration success rate?

Shenzhen Kangvape Technology Co., Ltd has a 77% trademark registration rate, with 20 out of 26 resolved applications resulting in successful registration. Currently, 4 applications are pending review.